HELP LINE:
844-775-2273
Customized support for patients with metastatic uveal melanoma (mUM) who have been prescribed KIMMTRAK® (tebentafusp-tebn)
About KIMMTRAK
CONNECT®
We offer proactive services and support tailored to your specific needs.
Financial assistance
Our team is here to help make your treatment more affordable.
Enroll
Enrolling in KIMMTRAK CONNECT
should be quick and easy.

KIMMTRAK CONNECT is a support program available at no cost for adult patients receiving KIMMTRAK infusion for the treatment of metastatic uveal melanoma (mUM). Sponsored by Immunocore, the program matches patients and caregivers with a dedicated nurse case manager who is US-based and provides customized support—from financial assistance to scheduling appointments to educational support.

Please see the KIMMTRAK Patient Information and Important Safety Information below including Boxed Warning for Cytokine Release Syndrome (CRS).

Watch this video to learn more about what KIMMTRAK CONNECT has to offer.



Customized support

Your dedicated nurse case manager will help guide you through the services and support we offer.



Financial assistance

We identify the options that are right for you. Once we understand your needs, we will help set you up with financial assistance.

Help with patient and site of care coordination

Just tell us what you need, and we will try to help you manage your care. We may be able to assist you in locating affordable transportation to and from your treatment. We can also help coordinate infusion appointments once you and your physician choose a treatment location.

Indication and Important Safety Information Including Boxed Warning

Usage

KIMMTRAK is a prescription medicine used to treat HLA-A*02:01-positive adults with uveal melanoma that cannot be removed by surgery or has spread.

Important Safety Information

What is the most important information I should know about KIMMTRAK?

KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including:

  • Cytokine Release Syndrome (CRS). Symptoms of CRS may include:
    • fever
    • tiredness or weakness
    • vomiting
    • chills
    • nausea
    • low blood pressure
    • dizziness and light-headedness
    • headache
    • wheezing and trouble breathing
    • rash

Tell your healthcare provider right away if you get any of these symptoms. Your healthcare provider will check for these problems during treatment with KIMMTRAK. Your healthcare provider may temporarily stop or completely stop your treatment with KIMMTRAK if you have severe side effects.

See "KIMMTRAK can cause other serious side effects" for more information.

Before receiving KIMMTRAK, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. KIMMTRAK may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with KIMMTRAK. For females who are able to become pregnant: For females who are able to become pregnant:
    • Your healthcare provider should do a pregnancy test before you start treatment with KIMMTRAK.
    • Use an effective form of birth control during treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.
  • are breastfeeding or plan to breastfeed. It is not known if KIMMTRAK passes into your breast milk. Do not breastfeed during the treatment with KIMMTRAK and for at least 1 week after the last dose of KIMMTRAK.

Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KIMMTRAK can cause other serious side effects, including:
  • Skin reactions. KIMMTRAK may cause skin reactions that require treatment. Tell your healthcare provider if you get symptoms of skin reactions—such as rash, itching, or skin swelling—that are severe and do not go away.
  • Abnormal liver blood tests. Your healthcare provider will do blood tests to check your liver before you start KIMMTRAK and during treatment with KIMMTRAK. Tell your healthcare provider if you get symptoms of liver problems such as right-sided abdominal pain or yellowing of the skin or eyes.
The most common side effects of KIMMTRAK include:
  • cytokine release syndrome (CRS)
  • rash
  • fever
  • itching
  • tiredness
  • nausea
  • chills
  • stomach pain
  • swelling
  • low blood pressure (symptoms may
    include dizziness or light-headedness)
  • dry skin
  • headache
  • vomiting
  • abnormal liver blood tests

These are not all the side effects possible with KIMMTRAK.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).

Please read the accompanying Patient Information Leaflet before you receive KIMMTRAK and discuss any questions you have with your healthcare provider.

Please see KIMMTRAK Patient Information.

Important Safety Information
Including Boxed Warning

What is the most important information I should know about KIMMTRAK?

KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including Cytokine Release Syndrome (CRS).

Usage

KIMMTRAK is a prescription medicine used to treat HLA-A*02:01-positive adults with uveal melanoma that cannot be removed by surgery or has spread.

Important Safety Information Including
Boxed Warning

What is the most important information I should know about KIMMTRAK?

KIMMTRAK can cause serious side effects that can be severe or life threatening and usually happen within the first three infusions, including Cytokine Release Syndrome (CRS).